Clinical Trials · NCT07651319
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- The Methodist Hospital Research Institute
- Enrollment
- 30
- Start date
- Jul 2026
- Locations
- 1 site, United States
- Primary endpoint
- To assess the safety and the tolerability of IL-2 plus Semaglutide in AD patients